膽道閉鎖治療市場規模、佔有率和成長分析：按療法、藥物、階段、給藥途徑、應用、最終用戶和地區分類－2026-2033年產業預測

2024 年全球膽道閉鎖治療市場價值為 11 億美元，預計從 2025 年的 11.7 億美元成長到 2033 年的 19.9 億美元，預測期（2026-2033 年）的複合年成長率為 6.8%。

全球膽道閉鎖治療市場涵蓋治療藥物、外科手術和診斷服務，旨在解決這種罕見的新生兒肝臟疾病。此疾病會導致進行性膽汁淤積，並造成嚴重的併發症。高死亡率凸顯了有效治療方法的迫切需求，推動了早期療育的發展，例如葛西氏門體造口術和前景廣闊的基因療法的臨床試驗。孤兒藥激勵政策正在加速該疾病（影響不到20萬名嬰兒）的治療研發，並透過腺結合病毒平台等技術進步推動市場成長，這些技術可用於改善膽汁流動。此外，人工智慧（AI）正在透過提高檢測準確性、加快藥物研發速度以及為每位患者量身定做個人化醫療，徹底改變治療方法。機器學習最佳化了診斷成像，預測分析實現了手術時機的個人化選擇；這些技術共同確保了治療效果的改善、成本的降低以及市場的永續成長。

全球膽道閉鎖治療市場按治療方法、藥物類型、疾病分期、給藥途徑、應用領域、最終用戶、分銷管道和地區進行細分。依治療方法分類，市場分為葛西氏肝門空腸吻合術、肝臟移植、藥物治療及支持性治療/營養管理。依藥物類型分類，市場分為熊去氧膽酸（UDCA）、抗生素、脂溶性維生素補充劑和其他藥物。依疾病分期分類，市場分為早期膽道閉鎖和晚期膽道閉鎖。依給藥途徑分類，市場分為口服和注射給藥。按應用領域分類，市場分為恢復膽汁流動、肝功能管理、營養支持和移植後護理。依最終用戶分類，市場分為醫院、兒童醫療中心、肝臟移植中心和門診診所。依分銷管道分類，市場分為醫院藥房、零售藥房和專科藥房。按地區分類，分為北美、歐洲、亞太、拉丁美洲以及中東和非洲。

全球膽道閉鎖治療市場的成長要素

微創技術的出現和葛西氏結腸造口術的進步顯著降低了術後併發症，縮短了住院時間，並改善了患者的肝功能。這促使醫療專業人員早期療育，並擴大了符合治療條件的患者群體。因此，對專用醫療設備和先進治療中心的需求不斷成長，隨著更多醫療機構採用創新的外科手術方案，市場成長也隨之增加。此外，術中影像和即時監測技術的引入提高了膽道重組的精確度，降低了再次手術的可能性，並改善了患者的預後。這增強了保險報銷的支持力度，並加速了區域和全球市場的擴張。

全球膽道閉鎖治療市場的阻礙因素

可供移植的供肝數量有限，對全球膽道閉鎖治療市場構成重大挑戰，限制了能夠接受根治性手術治療的患者數量。這種供不應求抑制了對移植相關技術和服務的需求。這是因為分配政策通常優先考慮緊急病例，導致許多候選人必須忍受漫長的等待。這種延誤降低了人們對移植相關產品的興趣，最終阻礙了市場發展。因此，安寧療護和過渡性治療越來越受到依賴，而這些治療對高附加價值細分市場的成長貢獻甚微。

全球膽道閉鎖治療市場趨勢

目前，全球膽道閉鎖治療市場正經歷顯著的轉變，即從單純依賴手術干預，轉向整合標靶分子療法，以解決潛在的病理學機制。借助基因組學和蛋白​​質組學的最新進展，研究人員正在開發創新藥物，這些藥物不僅可以減少纖維化和炎症，還能促進膽管再生。這一趨勢反映了精準醫療的日益普及，促使生物技術公司與兒童肝病中心開展合作，並加強了臨床試驗的研發。因此，全球膽道閉鎖兒童有望獲得更廣泛的治療選擇和更佳的長期預後。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢
• 疾病流行病學

全球膽道閉鎖治療市場規模：依治療類型分類

• 葛西門腸吻合術
• 肝臟移植
• 藥物治療
• 支持性護理和營養管理

全球膽道閉鎖治療市場規模：依藥物類型分類

• 熊去氧膽酸（UDCA）
• 抗生素
• 脂溶性維生素補充劑
• 其他

全球膽道閉鎖治療市場規模：依疾病階段分類

• 早期膽道閉鎖
• 進行性性膽道閉鎖

全球膽道閉鎖治療市場規模：依給藥途徑分類

• 口服
• 注射藥物

全球膽道閉鎖治療市場規模：依應用領域分類

• 恢復膽汁流動
• 肝功能管理
• 營養支持
• 移植後護理

全球膽道閉鎖治療市場規模：依最終用戶分類

• 醫院
• 兒童醫療中心
• 肝臟移植中心
• 門診部

全球膽道閉鎖治療市場規模：依通路分類

• 醫院藥房
• 零售藥房
• 專科藥房

全球膽道閉鎖治療市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Mirum Pharmaceuticals, Inc.
• Ipsen SA
• Takeda Pharmaceutical Company Limited
• Gilead Sciences, Inc.
• Travere Therapeutics, Inc.
• Calliditas Therapeutics AB
• Vivet Therapeutics SAS
• Generation Bio Co.
• Ultragenyx Pharmaceutical Inc.
• Abeona Therapeutics Inc.
• Orchard Therapeutics plc
• Sangamo Therapeutics, Inc.
• REGENXBIO Inc.
• Rectify Pharmaceuticals, Inc.
• Viking Therapeutics, Inc.
• Albireo Pharma（Ipsen）
• Ann & Robert H. Lurie Children's Hospital Research Programs
• Boston Children's Hospital Research Programs
• Children's Hospital of Philadelphia Research Programs
• King's College London Liver Research Program

結論與建議

Global Biliary Atresia Treatment Market size was valued at USD 1.1 billion in 2024 and is poised to grow from USD 1.17 billion in 2025 to USD 1.99 billion by 2033, growing at a CAGR of 6.8% during the forecast period (2026-2033).

The Global Biliary Atresia Treatment Market encompasses therapeutic drugs, surgical techniques, and diagnostic services addressing a rare neonatal liver disorder known for causing progressive cholestasis and substantial morbidity. The urgency for effective treatments is propelled by high mortality rates, prompting early interventions like Kasai porto-enterostomy and promising gene therapy trials. Orphan-drug incentives stimulate market growth by encouraging the development of therapies for this condition affecting fewer than 200,000 infants, leading to advancements like adeno-associated viral vector platforms for enhancing bile flow. Furthermore, artificial intelligence is revolutionizing treatment approaches through improved detection, expedited drug development, and personalized patient care. Machine learning optimizes diagnostic imaging, while predictive analytics enable tailored surgical timing, collectively enhancing outcomes, reducing costs, and ensuring sustained market progression.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Biliary Atresia Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Biliary Atresia Treatment Market Segments Analysis

The global biliary atresia treatment market is segmented by treatment type, drug type, disease stage, route of administration, application, end user, distribution channel and region. Based on treatment type, the market is segmented into Kasai Portoenterostomy, Liver Transplantation, Drug Therapy and Supportive & Nutritional Care. Based on drug type, the market is segmented into Ursodeoxycholic Acid (UDCA), Antibiotics, Fat-Soluble Vitamin Supplements and Others. Based on disease stage, the market is segmented into Early-Stage Biliary Atresia and Advanced Biliary Atresia. Based on route of administration, the market is segmented into Oral and Injectable. Based on application, the market is segmented into Bile Flow Restoration, Liver Function Management, Nutritional Support and Post-Transplant Care. Based on end user, the market is segmented into Hospitals, Pediatric Specialty Centers, Liver Transplant Centers and Ambulatory Care Centers. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Specialty Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Biliary Atresia Treatment Market

The emergence of minimally invasive techniques, along with advancements in the Kasai portoenterostomy procedure, significantly reduces postoperative complications, shortens hospital stays, and enhances liver function in patients. This encourages early intervention by healthcare professionals, expanding the eligible patient population for treatment. As a result, the demand for specialized devices and skilled treatment centers increases, driving market growth as more facilities adopt innovative surgical solutions. Additionally, the integration of intraoperative imaging and real-time monitoring contributes to more accurate biliary reconstruction, decreasing the likelihood of revisions and improving patient outcomes. This fosters stronger reimbursement support and accelerates market expansion both locally and globally.

Restraints in the Global Biliary Atresia Treatment Market

The limited availability of suitable donor livers for transplantation presents a significant challenge in the Global Biliary Atresia Treatment market, restricting the number of patients who can access a definitive surgical cure. This scarcity leads to a constrained demand for transplant-related technologies and services, as allocation policies often prioritize urgent cases, resulting in prolonged waiting times for many candidates. Such delays dampen enthusiasm for products associated with the transplant pathway, ultimately hindering market momentum. Consequently, there is a greater reliance on palliative or interim therapy options, which do not significantly contribute to the growth of high-value market segments.

Market Trends of the Global Biliary Atresia Treatment Market

The Global Biliary Atresia Treatment market is currently experiencing a notable shift towards the integration of targeted molecular therapies, which aim to address the underlying pathophysiology rather than relying solely on surgical interventions. By leveraging advancements in genomics and proteomics, researchers are developing innovative agents that not only mitigate fibrosis and inflammation but also promote bile duct regeneration. This trend highlights the growing emphasis on precision medicine, leading to collaborations between biotechnology companies and pediatric hepatology centers that enhance clinical trial pipelines. As a result, the market is expected to expand therapeutic options and improve long-term outcomes for children diagnosed with biliary atresia worldwide.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape
• Disease Epidemiology

Global Biliary Atresia Treatment Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Kasai Portoenterostomy
• Liver Transplantation
• Drug Therapy
• Supportive & Nutritional Care

Global Biliary Atresia Treatment Market Size by Drug Type & CAGR (2026-2033)

• Market Overview
• Ursodeoxycholic Acid (UDCA)
• Antibiotics
• Fat-Soluble Vitamin Supplements
• Others

Global Biliary Atresia Treatment Market Size by Disease Stage & CAGR (2026-2033)

• Market Overview
• Early-Stage Biliary Atresia
• Advanced Biliary Atresia

Global Biliary Atresia Treatment Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Injectable

Global Biliary Atresia Treatment Market Size by Application & CAGR (2026-2033)

• Market Overview
• Bile Flow Restoration
• Liver Function Management
• Nutritional Support
• Post-Transplant Care

Global Biliary Atresia Treatment Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Pediatric Specialty Centers
• Liver Transplant Centers
• Ambulatory Care Centers

Global Biliary Atresia Treatment Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Specialty Pharmacies

Global Biliary Atresia Treatment Market Size & CAGR (2026-2033)

• North America (Treatment Type, Drug Type, Disease Stage, Route of Administration, Application, End User, Distribution Channel)
  • US
  • Canada
• Europe (Treatment Type, Drug Type, Disease Stage, Route of Administration, Application, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Drug Type, Disease Stage, Route of Administration, Application, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Drug Type, Disease Stage, Route of Administration, Application, End User, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Drug Type, Disease Stage, Route of Administration, Application, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Mirum Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Travere Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Calliditas Therapeutics AB
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vivet Therapeutics SAS
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Generation Bio Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ultragenyx Pharmaceutical Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abeona Therapeutics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Orchard Therapeutics plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sangamo Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• REGENXBIO Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rectify Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viking Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Albireo Pharma (Ipsen)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ann & Robert H. Lurie Children's Hospital Research Programs
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Children's Hospital Research Programs
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Children's Hospital of Philadelphia Research Programs
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• King's College London Liver Research Program
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations